Background
==========

Over the last few years, one cannot open a clinical journal without an article ostensibly addressing some component of \'Personalized\' or \'Individualized\' or \'Precision\' medicine. This trend is particularly evident in the field of oncology. Personalized oncology is simply defined as \'getting the right treatment to the right patient at the right dose and schedule at the right time \[[@B1]\]. These papers usually report some component of the use of tumor biomarkers to better select which patients might be more likely to benefit from a given clinical care strategy, by virtue of either being more likely to respond or less likely to suffer toxicities.

The use of diagnostics to better treat patients is as old as medicine itself. Within the field of oncology, pathologic findings have been used to direct various chemotherapy regimens based on tissue of origin. More precisely, estrogen receptor (ER) has served as a predictive biomarker in breast cancer for selection of endocrine therapy since the mid-1970s \[[@B2],[@B3]\]. In the last 15 years HER2 has joined ER in breast cancer as a predictive factor, in this case serving as a marker for therapies directed towards the HER2 protein \[[@B4],[@B5]\]. More recently, other examples of useful biomarkers to direct novel targeted treatments in colorectal, lung, and hematologic malignancies have been reported.

Perhaps the most compelling stimulus for the interest in personalized medicine has grown from the omics-revolution of the last 15 years \[[@B6]\]. Based on the cloning of the human genome in the latter part of the 1990s, fascinating technologies that allow the simultaneous measurement of thousands of analytes (RNA, proteins, metabolites and so on) have been coupled with sophisticated bioinformatics to permit development of multi-parameter signatures that correlate with either biological or clinical phenotypes and outcomes.

Sadly, in spite of these amazing advances, only a few diagnostics have been adopted successfully into routine clinical care of patients with cancer \[[@B7]\]. Many reasons for the disappointing output of clinically useful tumor biomarkers have been addressed over the last decade \[[@B6],[@B8]-[@B12]\]. This commentary summarizes the reasons for the low output of clinically useful tumor biomarkers and also discusses the ways in which this is being addressed.

Addressing the lack of clinically useful tumor biomarkers
---------------------------------------------------------

In order that tumor biomarkers have clinical impact, there are two issues that must be addressed. First, it is important to distinguish a tumor biomarker from a tumor biomarker test. The term \'biomarker\' usually refers to a biological factor or process that is identified in malignant but not normal tissues or other biospecimens. In contrast, a tumor biomarker *test* is a specific assay for the biomarker. Indeed, it is possible that many tests may be developed for one tumor biomarker. HER2 offers an ideal example. HER2 can be over-expressed at the message and/or protein level, which can be a result of either amplification or regulatory control \[[@B4],[@B5]\]. Furthermore, activating HER2 mutations have recently been reported in breast cancers that have normal copy gene numbers \[[@B13]\]. Circulating extra-cellular domain of the HER2 protein levels may be detected in serum \[[@B7]\]. There are many tests that have been generated to identify and quantify these different circumstances, each with variable use in the clinic. Regardless, it is essential that any tumor biomarker that is to be used to direct care is accurate, reproducible, and reliable - put simply, it must have analytical validity \[[@B10]\].

Second, a tumor biomarker test must have clinical utility - a term coined by the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative in 2009 \[[@B10]\]. Clinical utility does not just imply that the tumor biomarker test divides a population into two separate groups with statistical significance (a circumstance EGAPP termed \'clinical validity\'). Rather, clinical utility is achieved if high levels of evidence have been generated that consistently demonstrate that applying the tumor biomarker test results in improved outcomes for the patient when compared to not using the assay to direct care. High levels of evidence may come either from prospectively directed clinical trials \[[@B14],[@B15]\] or from \'prospective retrospective\' studies using archived specimens derived from previously conducted clinical trials \[[@B11]\].

Although these concepts apply to any diagnostic in general, and to any tumor biomarker specifically, the advent of omics-based tumor biomarker studies has led to a plethora of reports of putative assays that are highly confounded by the astounding number of data points applied to a vanishingly small patient dataset. Recently, in a highly publicized situation, an unstable set of signatures that had no evidence of analytical stability was used to direct specific therapies within prospective clinical trials. This unfortunate set of circumstances led to a comprehensive review by a committee of experts, convened by the United States Institute of Medicine (IOM), of the translation of omics-based tests to clinical trials, and ultimately to clinical care \[[@B6]\]. The IOM committee generated a roadmap for investigators to follow during development of a putative new omics-based tumor biomarker test. This roadmap leads investigators through three separate but linked stages of development: Discovery, Test Development, and Evaluation of Clinical Utility and Use (Figure[1](#F1){ref-type="fig"}).

![**Institute of Medicine Roadmap for omics-based tumor biomarker test development.**The first stage encompasses discovery of a biologically, and perhaps clinically, interesting omics-based tumor biomarker and development of an analytically-validated tumor biomarker test with clinical validity. The second stage is directed towards evaluation for clinical utility and use of the tumor biomarker test, either in a prospective-retrospective study using archived specimens or in prospective clinical trials designed to \'test the test\' for its intended clinical use. Reprinted with permission from reference \[[@B6]\] by the National Academy of Sciences, Courtesy of the National Academies Press, Washington, D.C.](1741-7015-11-221-1){#F1}

A roadmap for the improvement of tumor biomarker research
---------------------------------------------------------

In a correspondence article in *BMC Medicine*\[[@B16]\], and in an accompanying companion paper published simultaneously in *Nature*\[[@B17]\], McShane and her colleagues extend these efforts to improve tumor biomarker research by providing a checklist of criteria for the use of omics-based predictors in clinical trials. This checklist grew out of a workshop convened by the United States National Cancer Institute (NCI), specifically to consider the recommendations from the IOM committee. The criteria pertain to all three stages of the IOM roadmap (Figure[1](#F1){ref-type="fig"}), but they are especially pertinent to investigators who have elected to cross the \'Bright Line\' illustrated in Figure[1](#F1){ref-type="fig"} that distinguishes the Discovery and Test Validation Stage from the Evaluation of Clinical Utility and Use Stage. The criteria are particularly directed towards those investigators who have chosen the strategy of conducting a prospective clinical trial to \'test the test\' (see Figure[1](#F1){ref-type="fig"}, middle and far right side of bottom panel). Of note, many of these criteria are not novel - indeed, McShane has worked tirelessly with many colleagues calling for transparent reporting of pre-analytical (the \'BRISQ criteria\') and study design and analytical (the \'REMARK criteria\') issues in papers describing tumor biomarker results \[[@B8],[@B9],[@B12]\]. However, the current publication is a comprehensive, yet concise, set of criteria about which any investigator considering a clinical trial to generate high levels of evidence for clinical utility of a tumor biomarker test must be aware.

Why is this checklist needed? Because, \'A Bad Tumor Marker Is as Bad as a Bad Drug \[[@B18]\]. Ironically, over the last century, the scientific community has developed very strict criteria for scientific discovery and reporting of both basic laboratory research and clinical trial investigations. For example, basic laboratory researchers follow a strict code of scientific methods ensuring proper experimental design, using appropriate control conditions and insisting on reproducibility. Likewise, clinical therapeutic trialists use prospectively written protocols that describe the objectives and subject eligibility for the trial and stipulate how the therapeutic agent will be prepared and administered. Moreover, the protocol states in great detail what endpoints will be evaluated and how they will be measured (with specific scales and criteria) and, finally, provides a specific statistical plan that must be followed during and at the conclusion of the trial. These features are designed to minimize unintentional, or intentional, biases and reporting, in an effort to produce believable, reproducible results - the hallmark of the scientific method.

For a variety of reasons, investigators who translate putative biomarkers from basic research to clinical studies have often ignored some of these fundamental principles of the scientific process. Rather, tumor biomarker investigations have, too often, been studies of convenience, in which the investigators have applied an assay (which may or may not have analytical validity) to some available patient specimens, observed separation in some outcome of the population at hand with a *P* value \<0.05, and declared victory. Although such a study may suggest clinical validity, the results rarely, if ever, demonstrate clinical utility. Unfortunately, very few investigators take the next step across the Bright Line into the Evaluation for Clinical Utility and Use Stage outlined in the IOM roadmap (Figure[1](#F1){ref-type="fig"}). Consequently, while thousands of manuscripts have been published in the peer-reviewed literature, few tumor biomarker tests have sufficiently high levels of evidence of clinical utility to warrant recommendations for use to direct patient care. The NCI Workshop criteria proposed by McShane *et al*, which are carefully explained in the *BMC Medicine* Explanation and Elaboration article \[[@B16]\], represent a further effort to provide a \'tour guide\' to accompany the roadmap laid out by the IOM Committee.

Conclusions
===========

Clearly, the scientific, regulatory, reimbursement, medical and lay communities do not value tumor biomarker tests to the same extent as cancer therapeutics. Recently, many of these concepts have been distilled into what has been designated a \'vicious cycle\' that emerges from the devaluation of tumor biomarker research and clinical application. Several transformative recommendations were suggested to break the cycle and create a \'virtuous cycle \[[@B19]\]. If we do not approach this problem systematically, as suggested by the IOM and the NCI Working Committee, the promise of personalized oncology will never materialize. Worse, assays of questionable value will be marketed to the public, *caveat emptor*, possibly resulting in unknown amounts of over- and under-treatment. It is essential that investigators considering generation of studies to develop Level 1 evidence supporting clinical utility of tumor biomarker tests be aware, cite and, more importantly, adhere to the criteria put forward by the NCI Workshop Committee.
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